GSK launches $2.5 billion buyback, lifts sales target
GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...
GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...
The stock market extended its winning streak on Wednesday, closing firmer as investors seemed to have already priced in the ...
GSK PLC closed 18.56% below its 52-week high of £18.24, which the company reached on May 16th.
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...
American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...
Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.
Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback